News | December 30, 2021
Sanofi loses appeal in the US over Lantus device patents
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Biocon Biologics and Viatris co-developed the products
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Subscribe To Our Newsletter & Stay Updated
